fashion -WSS

fashion

author：fashion 2025-09-06 02:11:12 - browse：2

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： A letter from the executive editor: STAT UnitedHealth investigation

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Experimental asthma app from Apple and Anthem shows promise

Philips to halt sales of sleep apnea machines in U.S.

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Medicare’s new pay boost for primary care is angering specialists

hotspot

fashion

explore

At least 13 dead in Texas as scorching temps continue

Philips to halt sales of sleep apnea machines in U.S.

Peter Hotez and the public health issue of online harassment

White House pharmacy plagued with problems, investigation finds

Bright Health sells Medicare Advantage business to Molina

Healthy food access boosts outcomes in two studies

Drug repurposing or repositioning? The language matters

What is STAT's opinion section for?

Medicare details structure of new drug price negotiation program

10 reasons why health care startups fail

explore

Study suggests Covid rebound is far more common with Paxlovid than without

Vertex non

FDA reorg will put new emphasis on investigations, sources say

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: Zepbound, Valneva's vaccine, and more

hotspot

Wikipedia

hotspot

leisure time